We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Clinical Announces New Investment In Translational Pharmaceutics™
News

Quotient Clinical Announces New Investment In Translational Pharmaceutics™

Quotient Clinical Announces New Investment In Translational Pharmaceutics™
News

Quotient Clinical Announces New Investment In Translational Pharmaceutics™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quotient Clinical Announces New Investment In Translational Pharmaceutics™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This investment is a direct response to the rapid rate of adoption of the Company’s Translational Pharmaceutics platform and unique approach by a growing international client base. 

Translational Pharmaceutics integrates formulation development, real-time manufacturing and clinical testing to offer shorter timelines, reduced costs and increased success rates in early phase drug development. The 25,000 ft2 expansion allows the extension of both the Pharmaceutical Development Laboratory and the Clinical Pharmacology Unit, which now has 85 beds and is accredited for all types of early clinical development programmes by the MHRA. The Company has also invested in spray-drying formulation and manufacturing capabilities – to address the development challenges of poorly soluble drugs – and established an in silico modelling group to support biopharmaceutical customers in defining formulation strategies and assessing in vitro-in vivo correlations (IVIVCs).

Mark Egerton, CEO of Quotient Clinical, commented: “Improving R&D productivity requires an evolution of traditional drug development processes. Our customers are attracted to our Translational Pharmaceutics platform to improve the efficiency of their early development programmes, and this latest round of investment enables us to extend our platform while continuing to offer rapid project start times.”

Advertisement